7 completed, 7 recruiting, 6 terminated, 5 active not recruiting. 30 Phase 1, 15 Phase 2.
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Rocbrutinib, R-GemOx - DLBCL | Phase 1 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 42 | 2026-06-25 | 2026-09-10 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL EZH2i+GLofit-GemOx - DLBCL | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 46 | 2026-06-01 | 2026-06-12 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Completed | Acepodia Biotech, Inc. | 16 | 2023-01-21 | 2026-06-30 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 67 | 2022-10-01 | 2022-08-19 |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) RNK05047 - Advanced Solid Tumor, DLBCL | Phase 1 / Phase 2 | Recruiting | Ranok Therapeutics (Hangzhou) Co., Ltd. | 32 | 2022-07-12 | 2025-03-04 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL KT-413 - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Kymera Therapeutics, Inc. | 7 | 2022-06-13 | 2024-12-10 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) IBI110 plus sintilimab, IBI110 - DLBCL | Phase 1 | Unknown | Innovent Biologics (Suzhou) Co. Ltd. | 50 | 2021-09-27 | 2021-09-09 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-11-04 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies L-Bcl-2 antisense oligonucleotide - Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Active not recruiting | Bio-Path Holdings, Inc. | 30 | 2020-11-05 | 2025-02-24 |
| Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement Lenalidomide, Rituximab, Etoposide - DLBCL, Untreated | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2020-06-09 | 2020-06-16 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | IGM Biosciences, Inc. | 97 | 2019-09-30 | 2024-07-24 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Fludarabine, Cyclophosphamide, CD22 CAR - B-ALL, B-cell Non Hodgkin Lymphoma | Phase 1 | Completed | Matthew Frank | 52 | 2019-09-12 | 2026-03-30 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, Follicular (10) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Mantle-Cell (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Waldenstrom Macroglobulinemia (4) · Lymphoma (3) · Lymphoma, B-Cell (3) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Pyloric Stenosis, Hypertrophic (2) · Recurrence (2) · Small Cell Lung Carcinoma (2)
Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Neoplasms by Histologic Type (18) · Neoplasms (17) · Lymphoma (15) · Lymphoma, B-Cell (12) · Lymphoma, Non-Hodgkin (8) · Disease Attributes (6) · Hematologic Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Blood Protein Disorders (5)
Cyclophosphamide (6) · Rituximab (6) · Doxorubicin (3) · Prednisone (3) · Vincristine (3) · fludarabine (3) · Etoposide (2) · Lenalidomide (2) · acalabrutinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · AZD5153 (1) · Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · Capecitabine (1) · E7777 fusion protein (1)
Acerta Pharma BV (2) · The First Affiliated Hospital with Nanjing Medical University (2) · The Lymphoma Academic Research Organisation (2) · Acepodia Biotech, Inc. (1) · Bio-Path Holdings, Inc. (1) · Cyteir Therapeutics, Inc. (1) · Genmab (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Hutchmed (1) · IGM Biosciences, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Ionis Pharmaceuticals, Inc. (1) · Kymera Therapeutics, Inc. (1) · Masonic Cancer Center, University of Minnesota (1)
United States (19) · China (7) · France (7) · Italy (5) · Spain (5) · Poland (4) · United Kingdom (4) · Australia (3) · Belgium (2) · Netherlands (2) · South Korea (2) · Ukraine (2) · Bulgaria (1) · Canada (1) · Czechia (1)
Ashwin Gollerkeri, MD (1) · Emmanuelle Tchernonog (1) · Franck Morshhauser, Pr (1) · Frank G Basile, M.D. (1) · Gilles Salles (1) · Ian Flinn, MD, PhD (1) · Juan Pinelli, PA-C, MMSc (1) · Julien Depaus (1) · Laura A Johnson, PhD (1) · Linda Grummer (1) · Loic Ysebaert, MD (1) · Mariano Provencio, MD, PhD (1)
PMID 28903943, PMID 30446007, PMID 32122924, PMID 33512414, PMID 34269152, PMID 34508654, PMID 35538512, PMID 36548927, PMID 38022532, PMID 38151388, PMID 38889737, PMID 38996463, PMID 39322711, PMID 40472301, PMID 42411504, PMID 42431612, PMID 42541678
2017 (2), 2015 (1), 2016 (1), 2023 (1), K08CA248968 (1)